» Articles » PMID: 29614332

New Therapeutic Approaches and Novel Alternatives for Organophosphate Toxicity

Overview
Journal Toxicol Lett
Publisher Elsevier
Specialty Toxicology
Date 2018 Apr 4
PMID 29614332
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Organophosphate compounds (OPCs) are commonly used as pesticides and were developed as nerve agents for chemical warfare. Exposure to OPCs results in toxicity due to their covalent binding and inhibition of acetylcholinesterase (AChE). Treatment for toxicity due to OPC exposure has been largely focused on the reactivation of AChE by oxime-based compounds via direct nucleophilic attack on the phosphorous center. However, due to the disadvantages to existing oxime-based reactivators for treatment of OPC poisoning, we considered non-oxime mechanisms of reactivation. A high throughput screen of compound libraries was performed to discover previously unidentified reactivation compounds, followed by studies on their analogs. In the process, we discovered multiple non-oxime classes of compounds, the most robust of which we have already reported [1]. Herein, we report other classes of compounds we identified in our screen that are efficient at reactivation. During biochemical characterization, we also found some compounds with other activities that may inspire novel therapeutic approaches to OPC toxicity. Specifically, we found compounds that [1] increase the rate of substrate hydrolysis by AChE and, [2] protect the enzyme from inhibition by OPC. Further, we discovered that a subset of reactivator compounds recover activity from both AChE and the related enzyme butyrylcholinesterase (BuChE). We now report these compounds, their activities and discuss how each relates to therapeutic approaches that would provide alternatives to traditional oxime-based reactivation.

Citing Articles

Application of in silico methods to predict the acute toxicity of bicyclic organophosphorus compounds as potential chemical weapon.

Noga M, Jurowski K Arch Toxicol. 2025; .

PMID: 40050428 DOI: 10.1007/s00204-025-04000-8.


A complete, evidence-based review on novichok poisoning based on epidemiological aspects and clinical management.

Charejoo A, Arabfard M, Jafari A, Hasani Nourian Y Front Toxicol. 2023; 4:1004705.

PMID: 36762227 PMC: 9905702. DOI: 10.3389/ftox.2022.1004705.


Synthesis, kinetic evaluation and molecular docking studies of donepezil-based acetylcholinesterase inhibitors.

Makarian M, Gonzalez M, Salvador S, Lorzadeh S, Hudson P, Pecic S J Mol Struct. 2022; 1247.

PMID: 35221376 PMC: 8881002. DOI: 10.1016/j.molstruc.2021.131425.


Discovery of Novel Non-Oxime Reactivators Showing In Vivo Antidotal Efficiency for Sarin Poisoned Mice.

Wei Z, Zhang X, Nie H, Yao L, Liu Y, Zheng Z Molecules. 2022; 27(3).

PMID: 35164361 PMC: 8840479. DOI: 10.3390/molecules27031096.


Role of penehyclidine in acute organophosphorus pesticide poisoning.

Yu S, Gao Y, Walline J, Lu X, Zhao L, Huang Y World J Emerg Med. 2020; 11(1):37-47.

PMID: 31893002 PMC: 6885584. DOI: 10.5847/wjem.j.1920-8642.2020.01.006.


References
1.
Millard C, Lockridge O, Broomfield C . Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry. 1995; 34(49):15925-33. DOI: 10.1021/bi00049a007. View

2.
Lorke D, Kalasz H, Petroianu G, Tekes K . Entry of oximes into the brain: a review. Curr Med Chem. 2008; 15(8):743-53. DOI: 10.2174/092986708783955563. View

3.
Musilek K, Dolezal M, Gunn-Moore F, Kuca K . Design, evaluation and structure-activity relationship studies of the AChE reactivators against organophosphorus pesticides. Med Res Rev. 2009; 31(4):548-75. DOI: 10.1002/med.20192. View

4.
Katz F, Pecic S, Tran T, Trakht I, Schneider L, Zhu Z . Discovery of New Classes of Compounds that Reactivate Acetylcholinesterase Inhibited by Organophosphates. Chembiochem. 2015; 16(15):2205-2215. PMC: 4664178. DOI: 10.1002/cbic.201500348. View

5.
Lenz D, Clarkson E, Schulz S, Cerasoli D . Butyrylcholinesterase as a therapeutic drug for protection against percutaneous VX. Chem Biol Interact. 2010; 187(1-3):249-52. DOI: 10.1016/j.cbi.2010.05.014. View